Can B Corp (CANB) - Net Assets

Latest as of September 2024: $-9.79 Million USD

Based on the latest financial reports, Can B Corp (CANB) has net assets worth $-9.79 Million USD as of September 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.86 Million) and total liabilities ($11.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CANB asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets $-9.79 Million
% of Total Assets -527.31%
Annual Growth Rate N/A
5-Year Change -115.74%
10-Year Change -1113.97%
Growth Volatility 197.44

Can B Corp - Net Assets Trend (2010–2023)

This chart illustrates how Can B Corp's net assets have evolved over time, based on quarterly financial data. Also explore Can B Corp (CANB) total assets for the complete picture of this company's asset base.

Annual Net Assets for Can B Corp (2010–2023)

The table below shows the annual net assets of Can B Corp from 2010 to 2023. For live valuation and market cap data, see Can B Corp market cap and net worth.

Year Net Assets Change
2023-12-31 $-1.00 Million -137.14%
2022-12-31 $2.70 Million -51.99%
2021-12-31 $5.62 Million +72.60%
2020-12-31 $3.26 Million -48.86%
2019-12-31 $6.37 Million +82.47%
2018-12-31 $3.49 Million +301.68%
2017-12-31 $-1.73 Million -236.17%
2016-12-31 $-514.59K -614.66%
2015-12-31 $99.99K +1.18%
2014-12-31 $98.82K +60.88%
2013-12-31 $61.42K +76.90%
2012-12-31 $34.72K -97.06%
2011-12-31 $1.18 Million +775.01%
2010-12-31 $-174.70K --

Equity Component Analysis

This analysis shows how different components contribute to Can B Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 9774011600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2023)

Component Amount Percentage
Common Stock $83.26 Million %
Other Comprehensive Income $119.59K %
Other Components $18.04 Million %
Total Equity $-1.00 Million 100.00%

Can B Corp Competitors by Market Cap

The table below lists competitors of Can B Corp ranked by their market capitalization.

Company Market Cap
Webac Holding AG
F:RKB
$2.23 Million
Baronsmead Venture Trust Plc
LSE:BVT
$2.23 Million
Ceylon Graphite Corp
V:CYL
$2.23 Million
Crown LNG Holdings Limited Warrants
NASDAQ:CGBSW
$2.23 Million
Augmentum Fintech PLC
LSE:AUGM
$2.23 Million
Astron Paper & Board Mill Limited
NSE:ASTRON
$2.23 Million
Reach PLC
LSE:RCH
$2.23 Million
G-Tec Jainx Education Limited
NSE:GTECJAINX
$2.22 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Can B Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2022 to 2023, total equity changed from 2,697,925 to -1,001,968, a change of -3,699,893 (-137.1%).
  • Net loss of 9,737,464 reduced equity.
  • Other factors increased equity by 6,037,571.

Equity Change Factors (2022 to 2023)

Factor Impact Contribution
Net Income $-9.74 Million -971.83%
Other Changes $6.04 Million +602.57%
Total Change $- -137.14%

Book Value vs Market Value Analysis

This analysis compares Can B Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-12-31 $-1493.16 $0.03 x
2011-12-31 $33.51 $0.03 x
2012-12-31 $0.89 $0.03 x
2013-12-31 $1.56 $0.03 x
2014-12-31 $2.50 $0.03 x
2015-12-31 $2.10 $0.03 x
2016-12-31 $-9.85 $0.03 x
2017-12-31 $-30.38 $0.03 x
2018-12-31 $37.04 $0.03 x
2019-12-31 $46.38 $0.03 x
2020-12-31 $13.82 $0.03 x
2021-12-31 $4.18 $0.03 x
2022-12-31 $0.76 $0.03 x
2023-12-31 $-0.08 $0.03 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Can B Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.00%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -451.70%
  • • Asset Turnover: 0.21x
  • • Equity Multiplier: 0.00x
  • Recent ROE (0.00%) is above the historical average (-743.36%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 0.00% -4877.56% 0.78x 0.00x $-1.10 Million
2011 -97.48% -55612.72% 0.00x 1.18x $-1.27 Million
2012 -4776.63% -6883.54% 0.09x 7.81x $-1.66 Million
2013 -521.78% -1959.51% 0.09x 2.93x $-326.64K
2014 -26.91% -81.64% 0.12x 2.74x $-36.47K
2015 -3848.95% -3734.76% 0.72x 1.43x $-3.86 Million
2016 0.00% -698.99% 0.69x 0.00x $-613.59K
2017 0.00% -1743.21% 0.56x 0.00x $-1.97 Million
2018 -117.87% -615.06% 0.18x 1.06x $-4.46 Million
2019 -72.14% -199.20% 0.33x 1.09x $-5.23 Million
2020 -175.58% -334.36% 0.30x 1.75x $-6.04 Million
2021 -216.56% -264.33% 0.28x 2.93x $-12.73 Million
2022 -553.17% -223.23% 0.43x 5.77x $-15.19 Million
2023 0.00% -451.70% 0.21x 0.00x $-9.64 Million

Industry Comparison

This section compares Can B Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $236,113,024
  • Average return on equity (ROE) among peers: -47.06%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Can B Corp (CANB) $-9.79 Million 0.00% N/A $2.23 Million
Aurora Cannabis Inc (ACB) $602.92 Million -11.50% 0.39x $197.35 Million
Akanda Corp (AKAN) $-3.83 Million 0.00% 0.00x $1.51 Million
Akebia Ther (AKBA) $74.01 Million -330.87% 6.15x $340.21 Million
Alkermes Plc (ALKS) $54.20 Million -73.99% 0.03x $4.62 Billion
Amylyx Pharmaceuticals Inc (AMLX) $-25.36 Million 0.00% 0.00x $1.77 Billion
Amphastar P (AMPH) $639.42 Million 21.51% 1.37x $959.02 Million
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $346.79 Million -104.36% 9.57x $3.81 Billion
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) $344.93 Million 26.40% 10.61x $3.57 Billion
Anika Therapeutics Inc (ANIK) $287.08 Million 1.44% 0.21x $199.00 Million
ANI Pharmaceuticals Inc (ANIP) $40.96 Million 0.73% 0.09x $1.80 Billion

About Can B Corp

NASDAQ:CANB USA Drug Manufacturers - Specialty & Generic
Market Cap
$2.23 Million
Market Cap Rank
#29577 Global
#5775 in USA
Share Price
$0.03
Change (1 day)
+6.91%
52-Week Range
$0.03 - $0.04
All Time High
$60.00
About

Can B Corp. develops, manufactures, and sells hemp biomass derived products containing cannabinoids. The company provides hemp cannabinoid products, including oils, creams, moisturizers, isolate, gel caps, spa products, concentrates, and lifestyle products. It sells its products under the Canbiola and Pure Leaf Oil brands through medical professionals under distribution agreements and its website… Read more